Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Accured Expenses (2016 - 2025)

Neurocrine Biosciences' Change in Accured Expenses history spans 16 years, with the latest figure at $76.5 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 1.03% year-over-year to $76.5 million; the TTM value through Dec 2025 reached $160.2 million, up 269.12%, while the annual FY2025 figure was $160.2 million, 269.12% up from the prior year.
  • Change in Accured Expenses reached $76.5 million in Q4 2025 per NBIX's latest filing, up from $55.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $124.4 million in Q3 2023 to a low of -$98.3 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $21.2 million, with a median of $17.1 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: surged 1691.67% in 2021, then tumbled 467.28% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $19.1 million in 2021, then surged by 96.86% to $37.6 million in 2022, then crashed by 361.44% to -$98.3 million in 2023, then soared by 178.64% to $77.3 million in 2024, then fell by 1.03% to $76.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Change in Accured Expenses are $76.5 million (Q4 2025), $55.8 million (Q3 2025), and $15.5 million (Q2 2025).